Free Trial
NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

$67.61
+0.07 (+0.10%)
(As of 03:21 PM ET)
Today's Range
$67.52
$67.69
50-Day Range
$66.47
$69.65
52-Week Range
$47.59
$69.68
Volume
185,992 shs
Average Volume
1.10 million shs
Market Capitalization
$3.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.73

Axonics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
4.6% Upside
$70.73 Price Target
Short Interest
Healthy
6.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
1.22mentions of Axonics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
407.69%
From $0.13 to $0.66 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.42 out of 5 stars

Medical Sector

290th out of 921 stocks

Surgical & Medical Instruments Industry

43rd out of 100 stocks

AXNX stock logo

About Axonics Stock (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock Price History

AXNX Stock News Headlines

Boston Scientific Bucks the Medtech Slow Down and Raises Outlook (AXNX)
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.
What 23 Analyst Ratings Have To Say About Eli Lilly and Co
Axonics Reports First Quarter 2024 Financial Results
Axonics Responds to ITC Action by Medtronic
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Axonics just downgraded at Morgan Stanley, here's why
Axonics just downgraded at Truist, here's why
Axonics just downgraded at CL King, here's why
Axonics just downgraded at Leerink, here's why
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/30/2024
Today
5/21/2024
Next Earnings (Estimated)
7/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AXNX
Employees
797
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.73
High Stock Price Target
$75.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+4.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-6,090,000.00
Pretax Margin
-3.60%

Debt

Sales & Book Value

Annual Sales
$366.38 million
Cash Flow
$0.13 per share
Book Value
$12.59 per share

Miscellaneous

Free Float
50,074,000
Market Cap
$3.45 billion
Optionable
Optionable
Beta
0.60
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

AXNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price target for 2024?

13 brokerages have issued 12-month price objectives for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they predict the company's share price to reach $70.73 in the next year. This suggests a possible upside of 4.6% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2024?

Axonics' stock was trading at $62.23 on January 1st, 2024. Since then, AXNX stock has increased by 8.6% and is now trading at $67.61.
View the best growth stocks for 2024 here
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) released its earnings results on Tuesday, April, 30th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.32. The company earned $91.41 million during the quarter, compared to analysts' expectations of $89.79 million. Axonics had a negative trailing twelve-month return on equity of 2.58% and a negative net margin of 4.12%. Axonics's quarterly revenue was up 29.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.19) earnings per share.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Axonics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.88%), Magnetar Financial LLC (2.25%), KRYGER CAPITAL Ltd (1.85%), Champlain Investment Partners LLC (1.75%), Bamco Inc. NY (1.35%) and Tokio Marine Asset Management Co. Ltd. (0.47%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXNX) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners